Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.

Laixin Wang, Ramesh K Prakash, C A Stein, Richard K Koehn, Duane E Ruffner
{"title":"Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.","authors":"Laixin Wang,&nbsp;Ramesh K Prakash,&nbsp;C A Stein,&nbsp;Richard K Koehn,&nbsp;Duane E Ruffner","doi":"10.1089/108729003768247637","DOIUrl":null,"url":null,"abstract":"<p><p>Oligonucleotide (ODN) therapy is a powerful tool for modulation of gene expression in vivo. With advances in ODN chemistry and progress in formulation development, ODNs are becoming widely acceptable drugs. This review summarizes the current status and future trend of the in vivo application of ODN therapeutics, especially antisense ODNs. Here, we review the current understanding of the tissue/organ distribution and cellular uptake of ODN drugs administered parenterally or nonparenterally to intact animals. The problems and advantages inherent in the use of different delivery methods for the treatment of particular diseases are discussed in detail. Emphasis is placed on the most widely studied ODN analogs, the phosphorothioates (PS). Lessons learned from antisense PS studies have broad implications for ODN therapeutics in general.</p>","PeriodicalId":7996,"journal":{"name":"Antisense & nucleic acid drug development","volume":"13 3","pages":"169-89"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/108729003768247637","citationCount":"34","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antisense & nucleic acid drug development","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/108729003768247637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 34

Abstract

Oligonucleotide (ODN) therapy is a powerful tool for modulation of gene expression in vivo. With advances in ODN chemistry and progress in formulation development, ODNs are becoming widely acceptable drugs. This review summarizes the current status and future trend of the in vivo application of ODN therapeutics, especially antisense ODNs. Here, we review the current understanding of the tissue/organ distribution and cellular uptake of ODN drugs administered parenterally or nonparenterally to intact animals. The problems and advantages inherent in the use of different delivery methods for the treatment of particular diseases are discussed in detail. Emphasis is placed on the most widely studied ODN analogs, the phosphorothioates (PS). Lessons learned from antisense PS studies have broad implications for ODN therapeutics in general.

治疗性寡核苷酸递送的进展:体内寡核苷酸的器官/细胞分布和靶向递送。
寡核苷酸(ODN)治疗是体内基因表达调控的有力工具。随着ODN化学的进步和配方开发的进步,ODN正在成为被广泛接受的药物。本文综述了ODN治疗药物,特别是反义ODN在体内应用的现状和未来趋势。在这里,我们回顾了目前对ODN药物的组织/器官分布和细胞摄取的理解,这些药物通过肠外或非肠外给药给药于完整的动物。详细讨论了使用不同给药方法治疗特定疾病所固有的问题和优点。重点放在最广泛研究的ODN类似物,硫代磷酸酯(PS)。反义PS研究的经验教训对ODN治疗具有广泛的意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信